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Abstract
Summary This report provides an overview and a comparison of the burden and management of fragility fractures in the largest
five countries of the European Union plus Sweden (EU6). In 2017, new fragility fractures in the EU6 are estimated at 2.7 million
with an associated annual cost of €37.5 billion and a loss of 1.0 million quality-adjusted life years.
Introduction Osteoporosis is characterized by reduced bone mass and strength, which increases the risk of fragility fractures,
which in turn, represent the main consequence of the disease. This report provides an overview and a comparison of the burden
and management of fragility fractures in the largest five EU countries and Sweden (designated the EU6).
Methods A series of metrics describing the burden and management of fragility fractures were defined by a scientific steering
committee. A working group performed the data collection and analysis. Data were collected from current literature, available
retrospective data and public sources. Different methods were applied (e.g. standard statistics and health economic modelling),
where appropriate, to perform the analysis for each metric.
Results Total fragility fractures in the EU6 are estimated to increase from 2.7 million in 2017 to 3.3 million in 2030; a 23%
increase. The resulting annual fracture-related costs (€37.5 billion in 2017) are expected to increase by 27%. An estimated 1.0
million quality-adjusted life years (QALYs) were lost in 2017 due to fragility fractures. The current disability-adjusted life years
(DALYs) per 1000 individuals age 50 years or more were estimated at 21 years, which is higher than the estimates for stroke or
chronic obstructive pulmonary disease. The treatment gap (percentage of eligible individuals not receiving treatment with
osteoporosis drugs) in the EU6 is estimated to be 73% for women and 63% for men; an increase of 17% since 2010. If all
patients who fracture in the EU6were enrolled into fracture liaison services, at least 19,000 fractures every year might be avoided.
Conclusions Fracture-related burden is expected to increase over the coming decades. Given the substantial treatment gap and
proven cost-effectiveness of fracture prevention schemes such as fracture liaison services, urgent action is needed to ensure that
all individuals at high risk of fragility fracture are appropriately assessed and treated.
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Introduction
The objective of this report is to provide information
on the current and future burden of osteoporosis and
associated fragility fractures as well as to describe cur-
rent management of the disease. Results are presented
for the five largest EU countries (France, Germany,
Italy, Spain and the UK) as well as Sweden, referred
to as the EU6. This report was developed by the
International Osteoporosis Foundation (IOF) and led
by a steering committee of scientific experts assigned
by the IOF. The report forms the basis of policy re-
ports prepared by IOF for each of the EU6 countries
[1–7] .
To facilitate an assessment and a comparison of the
burden and management of fragility fractures, a series
of metrics was defined by a steering committee and
thereafter quantified by a group of analysts at Quantify
Research (reflected in the authorship). The metrics were
classified into two broad categories with subcategories.
The first category was burden of disease with epidemi-
ology, economic cost and patient burden as subcate-
gories. The second category was management of disease
with service provision and service uptake as subcate-
gories. The first part of this report provides a summary
of the most important findings. An appendix that fol-
lows provides more detailed information on each metric,
particularly on the analytic methods.
Osteoporosis
Osteoporosis, which means porous bone, is a disease
that weakens the bones and increases the risk of fragil-
ity fractures, where bones can break from low level
impact or stress that would not normally break a
healthy bone. Since bones become more porous and
fragile with age, the disease is mainly found in the
older population, and is more common among women
than men [8].
Bone mineral density (BMD) is the measurement
used to determine whether an individual has osteoporo-
sis. The operational definition of osteoporosis is based
on the T-score for BMD in women [9, 10] and is de-
fined as a value for BMD 2.5 SD or more below the
young female adult mean (T-score less than or equal to
− 2.5).
The clinical relevance of osteoporosis lies in the
associated fragility fractures; until such an event oc-
curs, there are usually no symptoms [8]. In the
Western World, about 1 in 3 women and 1 in 5 men
above 50 years of age will fracture during their re-
maining life time [11]. After the age of 50 years, most
sites of fracture can be considered characteristic of os-
teoporosis. Fractures at the hip and vertebrae are
among the most common and serious sites of osteopo-
rotic fracture. Fragility fractures of the humerus, fore-
arm, ribs, tibia (in women, but not including ankle
fractures), pelvis and other femoral fractures after the
age of 50 years are fractures associated with low BMD
[12, 13].
Worldwide, osteoporosis causes more than 9 million
fractures a year, meaning there is a fragility fracture
every 3 s [14]. Those who have had their first osteo-
porotic fracture have a higher risk for further fractures.
The risk of fracture also increases with age, and as
average life expectancy around the world rises, more
individuals are expected to sustain fragility fractures.
The fracture-related monetary cost of fragility frac-
tures in the 27 countries of the EU (EU27) has been
estimated at €37 billion in 2010 [15], with 26,300 life
years lost and 1.16 million quality-adjusted life years
(QALYs) lost on a yearly basis [15]. With changing
demography, these costs are expected to increase con-
siderably by the year 2030.
Despite significant impacts on health and quality of
life for the older population, there is a general lack of
awareness of osteoporosis, including many health care
agencies, which results in suboptimal care. Indeed,
most individuals at high risk are never identified nor
given appropriate treatment, which gives rise to further
fragility fractures and worsening of health status.
The primary outcomes of interest in this report were
fractures considered to be related to low BMD [12].
These include clinical vertebral fractures, fractures of
distal forearm, pelvis-sacrum, ribs-sternum, clavicle,
humerus and proximal femur. Fractures of the hands,
feet, ankle, skull and facial bones were excluded. The
report also focuses on specific fracture sites: hip frac-
ture, clinical vertebral fracture and major osteoporotic
fracture (MOFs). MOF is a grouping of the most com-
mon fractures comprising hip, clinical vertebral, distal
forearm and proximal humerus fractures. The term
‘other’ osteoporotic fractures in this report refers to
osteoporotic fractures that are not MOFs unless specif-
ically defined. The majority of vertebral fractures are
subclinical (75%) and recognised on radiographs by a
change in shape of the vertebral body [10]. In the
present report, clinical vertebral fractures coming to
medical attention are considered rather than these mor-
phometric fractures.
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Epidemiology of fragility fractures
Prevalence of osteoporosis
About one-tenth of women age 60 years, one-fifth of
women age 70, two-fifths of women age 80 and two-
thirds of women aged 90 years have osteoporosis and
an increased risk of fragility fracture [16]. Worldwide,
approximately 200 million women have osteoporosis
[17] defined as a value for femoral neck BMD 2.5 SD
or more below the young female adult mean (T-score
less than or equal to − 2.5) [10]. Note that the BMD
threshold applies to men as well as women.
In 2015, there were an estimated 20 million individuals
with osteoporosis in the EU6. Of those, 15.8 million were
women and 4.2 million were men. The number of women
with osteoporosis increased markedly with age (Fig. 1). The
prevalence of osteoporosis at the age of 50 years or more, as
judged by femoral neck BMD, was 6.8% inmen and 22.5% in
women.
Country-specific estimates for individuals with the disease
age 50 years or older in women ranged from 21.8% (UK) to
23.1% (Italy). For men, the number with osteoporosis ranged
from 6.7% (Germany) to 7.0% (Italy). For country-specific
details and methods, see the Appendix (1: Prevalence of
osteoporosis).
Osteoporosis represents one of the greatest health
risks for individuals age 50 years or more, even when
compared to hypercholesterolaemia and hypertension
(two major contributors to heart disease), which affect
54% and 44% of people age 50 years or more, respec-
tively [18].
Number of fractures
There were estimated to be 2.7 million new fragility fractures
in the EU6 in 2017—equivalent to 7332 fractures/day (or 305/
h) (Table 1). Almost twice as many fractures occurred in
women (66%) compared to men. Hip, vertebral and distal
forearm/proximal humerus fractures accounted for 19.6, 15.5
and 17.9% of all fractures, respectively. Other fragility frac-
tures accounted for 49% of the fracture burden.
The number of new fragility fractures in 2017 by
country is shown in Fig. 2. Germany had the highest
number of fractures in both men and women—
approximately 765,000 incident fractures in total, pre-
dominately reflecting the large population size and com-
paratively high fracture incidence.
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Fig. 1 Prevalence of osteoporosis in the EU6 by age and sex
Table 1 Estimated number of
incident fragility fractures in the
EU6 by site in 2017
Fracture site Women Men Men and women
Hip 381,732 144,738 526,470
Spine 267,194 148,089 415,283
Proximal humerus/distal forearm 303,021 175,020 478,041
Other 819,029 437,397 1,256,426
All 1,770,976 905,244 2676,220
0
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500
600
France Germany Italy Spain UK Sweden
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Women Men
Fig. 2 Number (thousands) of new fragility fractures by country in 2017
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When fracture numbers were expressed as a rate of the
population at risk, there was a greater than two-fold range in
risk that varied from 15/1000 in France to 32/1000 in Sweden
(Table 2).
A detailed breakdown of number of fractures by site
and country is given together with the methods in the
Appendix (2: Lifetime risk of fragility fractures).
Lifetime risk of fragility fracture
The remaining lifetime risk of sustaining a hip fracture
for women at the age of 50 years varied between 9.8%
for Spain to 22.8% for Sweden (Fig. 3). The corre-
sponding risk range for men was 6.1% (France) to
13.7% (Sweden). The lifetime risk of hip fracture at
age 50 years was comparable to the lifetime risk of a
stroke in Europe for both women (20%) and men (14%)
[22].
The remaining lifetime probability of a MOF was
highest in Sweden (46.3% for women and 28.7% for
men (Fig. 4). Lifetime risk of major osteoporotic fracture
was comparable to that of cardiovascular disease (CVD)
in Europe, which affects 29% of women and 38% of men
[19]. For methods and numerical data by fracture site and
country, see the Appendix (2: Lifetime risk of fragility
fractures).
Fracture projections
There is a marked difference in the risk of fracture
between countries [20]. Northern European countries
have the highest fracture rates observed worldwide.
The reasons for the difference in fracture risk are un-
known but cannot be explained by differences in bone
density. Plausible factors include differences in body
mass index, low calcium intake, reduced sunlight expo-
sure and perhaps the most crucial factor, high socio-
economic status, which in turn may be related to low
levels of physical activity [21, 22]. Regardless of differ-
ences in fracture risk, the number of fractures in all
countries is expected to increase due to an increasingly
ageing population.
To estimate the annual number of new fractures be-
tween 2017 and 2030, national data on fracture incidence
by type and sex were combined with demographic pro-
jections over time (see Appendix, 3: Fracture projec-
tions). The total number of all fragility fractures in the
EU6 is projected to increase from 2.7 million in the year
2017 to 3.3 million in 2030; an increase of 23.3%
(Fig. 5). In total, 66.2% of fragility fractures were
sustained by women in 2017. The total number of
MOF was 1.4 million and expected to increase by
24%. For hip fracture (n = 526 thousand) and clinical spine
fracture (n = 416 thousand), the increases projected were 28%
and 23%, respectively.
Variations in projections were seen between countries
(Fig. 6). For example, the highest percentage increase in
all osteoporotic fractures was noted in Spain (28.8%) and
the lowest in Germany (18.5%), due to differences in
Table 2 The number of new fragility fractures in 2017 in men and
women by country, the population at risk (men and women aged
50 years or more) and the crude incidence (/1000 of the population)
Country New fractures (000) Population at risk (000) Rate/
1000
France 381.6 24,672 15
Germany 764.9 33,399 23
Italy 563.4 26,282 21
Spain 327.6 16,510 20
UK 519.0 24,048 22
Sweden 119.7 3787 32
EU6 2676.2 128,699 21
0
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Fig. 3 Lifetime risk of hip fracture from the age of 50 years, by country
and sex, and the equivalent risk for stroke
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Fig. 4 Lifetime risk of fragility fracture from the age of 50 years, by
country and sex, and the equivalent risk for cardiovascular disease
(CVD). Source: National fracture incidences and own calculations
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projected populations over time up to 2030. Country-
specific details for hip, vertebral fractures and MOFs are
given in the Appendix (3: Fracture projections).
Imminent risk of fracture
Individuals who have already suffered a fragility fracture
are at a greater risk for further fractures both at the same
site and elsewhere. This additional risk of refracture is
highest immediately after a fracture [23]. Figure 7 shows
the risk per 100,000 women at the age of 75 years fol-
lowing a MOF. The high subsequent fracture risk ob-
served during the first two years following the fracture
has been referred to as the period of imminent risk [23,
24]. The existence of an imminent risk period signals that
there is an opportunity to optimize the benefits of fracture
prevention treatments if patients could be identified and man-
aged as soon as possible after fracture.
Available evidence shows that similar patterns of im-
minent fracture risk are observed in all countries where
this has been explored [25–31]. However, there is little
information to assess whether there are differences in
imminent fracture risk between countries. Findings from
Sweden are given in the Appendix (4: Imminent fracture
risk).
The empirical 10-year probability of MOF was consis-
tently higher in those with a sentinel clinical vertebral frac-
ture within the past two years than the FRAX probability in
the population of the same age with any previous fracture,
but the relative risk (observed/expected probability) varied
by age. For example, the relative risk at the age of 50 years
for a woman with a clinical vertebral fracture within the
previous 2 years was 2.5; for the age of 80 years, the ratio
was 1.2 (Table 3).
The impact of the adjustment in the EU6 countries is
illustrated in Table 4 which shows the impact of a re-
cent clinical vertebral fracture on conventional FRAX
probabilities.
Thus, 10-year FRAX probabilities can be adjusted in the
presence of a recent vertebral fracture and are likely be
useful in treatment decision-making. Similar adjustments
for recent fractures at other sites are a requirement for the
future.
Economic cost of fragility fractures
Fracture costs and length of hospital stay
Fragility fractures incur both short-term and long-term
costs for the health care sector and for society. These costs
differ between fracture sites, and to some extent reflect the
severity of fracture, in particular the need for hospital
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Fig. 5 Estimated number of fragility fractures by fracture category in
2017 and 2030. Numbers denote the percentage change for all fragility
fractures, major osteoporotic fractures (MOF), hip and clinical spine
fractures
Fig. 7 Risk per 100,000 (95%CI) of a secondMOF after a firstMOF for a
woman at the age of 75 years at her first fracture [23]. The dashed line
represents the risk of first MOF in the age- and sex-matched population
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Fig. 6 Number of fragility fractures by country in the EU6 and the
projected numbers in 2030
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admission. Hip fractures are the most severe fracture site,
and almost always lead to hospitalization and high costs.
The length-of-hospital-stay is an important cost component
and, within country, has also been shown to have implica-
tions for how patients fare over their remaining life time
[33].
In the EU6, the average length-of-hospital-stay for hip frac-
ture ranged from 11.6 days in Sweden, to 20.5 days in the UK
(Table 5). Methods are given in the Appendix (5: Length of
hospital stay).
The unit fracture costs differed substantially between
countries and fracture sites (Table 6). Hip fractures were
the costliest fracture type in all countries, whilst distal fore-
arm fractures were the least costly. Fracture costs were
generally high in Sweden and Germany, and the lowest in
Spain. For more details, see the Appendix (6: Fracture-
related costs).
Annual fracture-related costs
If current trends in fracture prevention continue, as the general
population grows and lives for longer, the hospital and societal
cost of fragility fractures will continue to increase.
The fracture-related costs in the EU6 amounted to €37.5
billion in the year 2017. Hip fractures accounted for the ma-
jority of the total cost (57%) whereas they accounted for 20%
of fragility fractures (Fig. 8).
The direct cost of fractures in each EU6 country is
given in Table 7. Costs comprise the annual cost of frac-
tures in 2017 (incident fractures), those arising from frac-
tures before 2017 (prior fractures) and the cost of institu-
tional care.
In 2010, fracture-related costs in the EU6 were estimat-
ed to total €29.6 billion [39]. Fracture-related costs for the
EU6 in 2017 were now estimated to total €37.5 billion (an
increase of 27% since 2010), and are projected to increase
to €47.4 billion in 2030 (an increase of 27% since 2017)
(Fig. 9).
As expected, costs will increase due to the increase in
fracture cases. The fracture-related costs in the EU6 are
projected to increase by 27% from a total €37.5 billion in
the year 2017 to €47.4 billion in 2030. Cost projections to
2030 are shown for each country by fracture site in Fig. 10.
The dominant cost was for hip fracture. The fracture-
related cost estimates provided are conservative, since
costs from other fracture sites were not included in the
estimation.
There were small variations in the percentage increase in
cost by country. The greater increases were noted in Spain
Table 3 Ten-year probability of a
major osteoporotic fracture
(MOF) for Icelandic women at
different ages, categorized by
previous fracture [32]
10-year probability of MOF
Age Cohort with clinical vertebral
fracture 0–2 years ago
Cohort with any previous
fracture in adult life
Ratio
50 29.0 11.7 2.47
60 36.1 19.4 1.86
70 41.9 27.6 1.52
80 42.5 34.2 1.24
90 34.7 33.3 1.04
Table 4 Ten-year probability of a major osteoporotic fracture (MOF) in
women with a prior clinical vertebral fracture at an undetermined time
and within the past two years according to country. Age set to 60 years,
BMI 25 kg/m2, no additional risk factors [32]
Probability MOF (%)
Country Undetermined time Within the past 2 years
France 9.4 17
Germany 12 22
Italy 12 22
Spain 7.0 13
Sweden 21 39
UK 16 30
Table 5 Mean length of hospital stay (LOS) and standard deviation
(SD) following a hip fracture
Country LOS (days) Source
Mean SD
France 12 8.0 [34]
Germany 14.5 (2.6) 2.6 [35]
Italy 19.0 (25.3) 25.3 [36]
Spain 11.8 (7.9) 7.9 [37]
Sweden 11.6 (8.7) 8.7 [33]
UK 20.5 (20.0) 21.6 [38]
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(+30.6%), the UK (+30.2) and Sweden (+29.4%) and lower
increments in Germany (+23.2%), Italy (+26.2%) and France
(+26.4%).
Cost for incident fractures in a given year and long-term
cost (due to fractures that arose in previous years), as well as
the cost of residing in nursing homes, are detailed in the
Appendix (7: Annual cost of fractures).
Patient burden
Quality-adjusted life years
The use of QALYs is a method of measuring the burden of a
disease where a year of an individual’s life is weighted by the
average health-related quality of life (HRQoL) that a person
had during that year. For example, 1 QALY is equal to one
year spent in perfect health; 0.5 QALYs can be thought of as
either half a year spent in perfect health followed by death, or
one year lived at 50% of perfect health. QALYs are regularly
used in economic analyses because they provide decision
makers with a method for quantifying and comparing burden
across diseases.
QALYs lost due to fragility fractures were estimated from
fracture-based HRQoL, fracture risks and death rates [40–42].
Methods are summarised in the Appendix (8: Quality-
adjusted life years). Estimates of the QALY loss were gener-
ated from 2017 up to year 2030, based on population projec-
tions, to show the expected change in QALY loss for the near
future.
Number of fractures
Hip
20%
Spine
16%
Humerus     
forearm
15%
Other
49%
Hip
57%
Spine
8%
Humerus     
forearm
33%
Other
2%
Cost of fractures
Fig. 8 Number and cost of fragility fractures in the EU6 expressed as a
percentage of the totals. Note: The estimates conservatively assume no
long-term costs for ‘other fractures’
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Fig. 9 Annual cost of fractures by site in the EU6 for 2017 and projected
increase by 2030
Table 7 The direct cost (million Euro) of fractures in 2017 (incident
fractures), those arising from fractures before 2017 (prior fractures) and
the cost of institutional care in each EU6 country
Country Incident fractures Prior fractures Institutional care Total
France 3748 219 1404 5371
Germany 8176 414 2680 11,270
Italy 5951 299 3179 9429
Spain 2150 137 1915 4202
UK 2955 372 1919 5246
Sweden 1199 81 690 1970
Table 6 Mean cost of fracture (€ 2017) in the year following fracture at
the sites shown
Country Hip Vertebral Distal forearm
France 12,856 3205 1468
Germany 20,884 11,080 1275
Italy 21,307 4713 1301
Spain 9724 1928 533
Sweden 16,406 14,474 4028
UK 20,650 4028 2568
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The total health burden in 2017 due to fragility fractures
in EU6 was at 1.02 million QALYs. 66% of the QALY loss
was due to fractures occurring in women. The QALY loss
in absolute numbers was highest in Germany due to the
size of the population combined with comparatively high
risk of fractures. The lowest QALY loss was observed in
Sweden due to the small population size compared to the
other countries. On a per capita basis, Sweden had the
largest burden (4.22 lost QALYs per 1000 people age
50 years and above) and France the lowest (2.11 lost
QALYs per 1000) (Fig. 11). The differences were driven,
in large part, by differences in the risk of fractures and age
distribution between countries.
The QALY burden is expected to increase by 25.6% in the
year 2030 but varied by country (Fig. 12).
Disability-adjusted life years
The DALY (or disability-adjusted life year) is the World
Health Organization’s (WHO) standard method of mea-
suring the burden of a disease. DALYs are the sum of
years of life lost (YLL) and the years lost due to
disability (YLD) [46]. A single DALY can be thought
of as one year of ‘healthy life’ lost. Summing the
DALYs across an entire population provides the gap
between the current health status of a population and
an ideal disease-free population, i.e. the burden [43].
Including this measure of burden allows for comparison
of the burden of different diseases, both within and
between countries.
When using the WHO standard method, the total DALYs
related to fragility fractures in year 2016 for the EU6 (ages of
50 to 100 years) were more than 2.6 million DALYs. Average
YLDs per 1000 people (15.1) far exceeded the YLLs per 1000
(5.5), indicating that living with a disability due to fracture
drives DALY loss in osteoporosis.
The DALY burden was less for hip fracture than for verte-
bral fracture which, in turn was less than for other fragility
fractures (Fig. 13). This dominance of other fragility
fractures over hip fractures arose from the combination
of a high incidence at early ages, and the large number
of years spent with disability from other fractures com-
pared with hip fracture.
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Fig. 13 Total DALY distribution by fracture site
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Fig. 12 Quality of life years (QALYs) lost due to fragility fractures in
countries of the EU6 in 2017 and 2030
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Fig. 11 Quality of life years (QALYs) lost in 2017 due to fragility frac-
tures per 1000 of the population age 50 years or more in countries of the
EU6
0
2
4
6
8
10
12
14
16
2017 2030 2017 2030 2017 2030 2017 2030 2017 2030 2017 2030
Cost (€ billions)
Hip Vertebral Other
France Germany Italy Spain Sweden UK
Fig. 10 Cost of fragility fractures in 2017 and that expected in 2030 by
country and fracture site
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The age distributions of YLLs and YLDs differed by
fracture site. In women with hip fractures (Fig. 14), the
YLLs peaked at the age of 77 years, whilst the YLDs
peaked at age 81 years, reflecting that most hip fractures
occur around 77 years. The YLDs for non-hip, non-
vertebral fractures in the female population (Fig. 15),
peaked early and was sustained over age, with very low
YLLs, indicating that prevalence of non-hip, non-vertebral
(NHNV) fractures is high but with limited consequences
for mortality when compared with to that following hip
fracture. The equivalent data for men are given in the
Appendix (9: Disability-Adjusted life years).
The total DALY for each country varied greatly due to
differences in population demography and fracture risk
(Fig. 16). The average DALY loss per 1000 individuals
was estimated to be 21 DALYs, with Sweden showing the
highest rate (32 DALYs) and Spain showing the lowest
(12 DALYs).
The DALYs related to fragility fractures can be compared
to corresponding estimates for other diseases. In Fig. 17, fra-
gility fracture-related DALYs are compared to 16 other com-
mon non-communicable diseases in the EU6 [44]. Among
these, fragility fractures are placed as the fourth most burden-
some, outranked only by ischemic heart disease, dementia and
lung cancer.
The DALY burden by disease category varied between
countries due to differences in age distribution, risk of fracture
and death. The DALY burden also varied by disease category.
In Sweden, for example, the DALY burden of fractures was
higher than that for dementia whereas in Spain the burden
related to dementia, lung cancer and COPD surpassed that
for fractures. For more details, see the Appendix (9:
Disability-adjusted life years and 11: DALY comparison
across diseases). The metrics also provide details of the
DALY distribution by fracture site.
From a national perspective, the DALY loss rate can be an
important measure for motivating policy decisions and the
prioritization of funds towards osteoporosis treatment. From
an international perspective, the high values suggest a need for
better treatment policy and practice.
Loss of productivity
Most fragility fractures occur in older retired patients.
If, however, individuals sustain a fracture whilst still
employed they will likely need to take time off from
work to recover from the fragility fracture. In Sweden,
for example, about 20% of fractures occur at pre-
retirement age [11]. Work absence both impacts the in-
dividual’s income and creates a societal cost due to the
loss of productivity.
To measure this loss of productivity, data collected in
the Internat ional Costs and Uti l i t ies Related to
Osteoporotic Fractures Study (ICUROS) [41, 45, 46] were
used to estimate the number of sick days taken by non-
retired individuals from the ages of 50 to 65 years in the
year following an osteoporotic fracture. Since Germany
was not included in the 11 countries that made up the
ICUROS study, a combination of the other 5 countries,
as well as Austria and Estonia, termed ICUROS Europe,
was used as a substitute measure for the EU6. Average
sick days were combined with fracture projection data to
estimate the total sick days taken due to fragility fractures
in 2017, by non-retired individuals. Because there are no
appropriate data on the proportion of the population that
work beyond the age of 65 years, a retirement age was set
at 65 years for all countries in the calculations. For more
details, see Appendix (11: Productivity loss).
Hip fractures resulted in the highest number of sick
days taken in the first year after fracture (42 days),
followed by vertebral fractures (20 days) and other
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Fig. 14 Total DALYs by age for hip fractures in women
Arch Osteoporos           (2020) 15:59 Page 9 of 21    59 
MOFs (12 days). Sick days taken in 2017, by non-
retired individuals in the EU6 totalled 7,615,719 days.
The other MOFs (distal forearm and proximal humerus
fracture) arose more often than hip or clinical vertebral
fractures, and therefore resulted in the highest number
of sick days.
When sick days taken due to fragility fracture were
expressed per 1000 people age 50 to 65 years in all countries,
Sweden had the highest estimate of the EU6 countries
(Fig. 18). There were no significant differences between sick
leave taken by men and women with hip fractures, nor be-
tween sick leave taken by hip fracture patients with or without
previous fracture.
Caregiver burden
Another significant burden associated with fragility fractures
and other diseases is the burden imposed on informal
caregivers such as family members. Continued care provided
at home can put physical, emotional and financial strain on
relatives who need to take care of osteoporotic fracture pa-
tients [15, 47]. To measure the average burden placed on in-
formal caregivers per year, survey responses from the
ICUROS [41, 45, 46] were also used to determine the care-
giver burden due to osteoporotic fracture. It was measured in
terms of hours of care per year provided by relatives of frac-
ture cases in ICUROS Europe (a substitute measure for the
EU6), as well as selected countries. For methods and estimates
by fracture type, see the Appendix (12: Caregiver burden).
Hip fractures were associated with the largest caregiver
burden (370 h per year), followed by vertebral fractures
(263 h per year) and other MOFs (130 h per year). Hours of
care provided by relatives varied greatly by country. In coun-
tries where cross-generational support is more established, the
impact of fragility fractures on caregivers is generally higher
[48]. Accordingly, Spain and Italy had the highest caregiver
burden, with averages of 756 h and 882 h a year, per 1000
individuals, spent caring for patients with osteoporotic hip
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fractures, respectively. France (138 h) and Sweden (191 h) had
considerably lower averages (Fig. 19). There were no signif-
icant differences in care from relatives between men and
women, nor between patients with or without a previous
fracture.
Independent living
One major burden caused by fragility fractures is the long-
term impact on independence. The fracture can result in a loss
of mobility, the ability to take care of oneself, and may require
the individual to move into long-term care (LTC) or care ser-
vices [49]. The ICUROS provided survey responses for the
percentage of individuals who needed to move into LTC as a
direct result of an osteoporotic fracture. For methods, see the
Appendix (13: Independent living).
LTC use varied greatly, depending on the fragility fracture
and the age of the individual. Hip fractures result in the largest
proportion of people moving to LTC in ICUROS Europe
(Fig. 20).
The percentage of patients moving into LTC follow-
ing a hip fracture increased significantly with age, from
2.1% at ages 50–60 years to 35.3% at ages 90–100 years
(Fig. 21).
Fracture prevention
Pharmacological treatment gap
The treatment gap (i.e. the number of women that are treated
compared to the proportion of the population that could be
considered eligible for treatment) in osteoporosis has been
estimated for the European Union using international sales
data on volume (standard units) and price (€) from IMS
Health for year 2010 [15, 50]. Applying the same methodol-
ogy, an update of the treatment gap was conducted using IMS
sales data for year 2017. The analysis included data on sales9
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related to all osteoporosis drugs (bisphosphonates,
denosumab, parathyroid hormone and peptides, selective
oestrogen receptor modulators (SERMs) and strontium
ranelate). Menopausal hormone treatment (MHT) was not
included.
The treatment gap was estimated from the difference be-
tween the number of patients treatedwith an osteoporosis drug
using IMS sales data and the number of patients in the popu-
lation considered to be eligible for an osteoporosis treatment.
Fur ther de ta i l s are g iven in the Appendix (14:
Pharmacological treatment gap). In line with European guide-
lines [51], patients eligible for treatment have a country- and
age-specific MOF fracture probability equivalent to a woman
with a prior fragility fracture based on the FRAX algorithm.
The calculation of the treatment gap assumes that all treat-
ments are given to patients above the intervention threshold.
The approach does not take account of differences in treat-
ment guidelines between countries.
The average treatment gap (percent eligible patients not
treated) in EU6 in year 2017 was 73% for women and 63%
for men (Fig. 22). The higher gap in women was the case in all
countries with the exception of Germany which had the
highest treatment gap. Only 20% of eligible men and 22%
of women in Germany would receive a pharmacologic inter-
vention. The treatment gap varied between countries. The
highest treatment gap for women was in Germany, whereas
the UK had the smallest treatment gap (64%) in women and in
men (43%).
Changes in the treatment gap between 2010 and 2017 are
shown for men (Fig. 23) and women (Fig. 24). Compared to
the analysis from year 2010, there was a marked increase in
the treatment gap for the EU6 (17% and 16% points for wom-
en and men, respectively). This increase was mainly driven by
large changes in France and Spain. The adverse changes in
treatment gap were most marked in France (38 percentage
points increase in men and 34 percentage points in women),
and Spain (by 40 and 43 percentage points increase in men
and women, respectively). The treatment gap increased to a
lesser extent in Italy and was relatively stable in Germany,
Sweden and the UK.
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Post-fracture treatment gap
An alternative approach for assessing the treatment gap is to
estimate the proportion of patients starting a pharmacological
treatment after a fracture. Available estimates were gathered
from a mix of literature, public reports (France [52] and the
UK [53]), data on file at UCB (Spain) and data on file at
Quantify Research (Sweden). The percentage of women who
did not receive osteoporosis-specific pharmacological treat-
ment within a year of an osteoporotic fracture is shown in
Fig. 25. The analytic methods vary between the estimates mak-
ing direct comparisons difficult. However, the post-fracture
treatment gap can be considered large irrespective of country.
With the exception of the UK, no more than 30% of women
receive a treatment following a fracture. In the UK, the treat-
ment gap was markedly lower after hip fracture (49%). For
more details, see the Appendix (15: Fracture treatment gap).
A more detailed analysis, using the Swedish National Patient
Register (NPR) and the Swedish National Prescription Register,
was conducted to explore differences in the treatment gap for
different subpopulations. Patients were defined as treatment-
naïve if they had not collected any prescriptions for anti-
osteoporotic medications during the three years prior to the
fracture.
At the time of fracture, most women (89%) and men (97%)
were treatment naïve. Figure 26 shows the pattern of treatment
following a fracture by treatment exposure in women. Within
the year following a hip fracture, a MOF or any fragility frac-
ture, only 11% to 12% of treatment-naïve women started treat-
ment for osteoporosis. Following a vertebral fracture, 26% of
treatment-naïve women started treatment. A similar pattern
was observed in the male population although treatment gaps
were in general higher (Fig. 27). About 5% of treatment-naïve
men were treated following a hip fracture, or a MOF.
Following a vertebral fracture, 11% of treatment-naïve men
started treatment.
In men and women who had previously been exposed to
therapies for osteoporosis, the treatment gap was substantially
lower than in treatment-naïve patients. These finding illustrate
important issues in that a new treatment is rarely offered to (or
taken up by) patients after fracture and, even in patients pre-
viously exposed to osteoporosis treatment, only about half
receive a treatment within the next year.
A limitation of this analysis is that the Swedish National
Patient Register (SNPR) does not cover drugs dispensed at the
hospital (mainly intravenous and subcutaneous administered
medications), which are estimated to comprise 4% of medi-
cines sold [54]. This likely leads to a slight overestimation of
the treatment gap. For more details, see the Appendix (16:
Treatment gap by fracture type).
Table 8 Risk models and
guidelines available in the
countries of interest
Countries FRAX model
available
Other models National
guidance
Comments Source
France Yes – Yes [63]
Germany Yes DVO Model Yes [59]
Italy Yes FRAHS,
DeFra
Yes FRAHS:
FRAX-based
[64–66]
Spain Yes – Yes [67]
Sweden Yes – Yes [68]
UK Yes QFracture Yes [69]
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Fig. 27 Percentage of men untreated within one year of fracture by site of
fracture and prior exposure to osteoporosis treatment in Sweden. N,
treatment-naïve; E, prior exposure
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Fracture risk assessment
Although osteoporosis is defined in terms of BMD, there are
several other factors that are associated with an increased risk
of fracture that are not captured by BMD. This has led to the
development of risk models, which incorporate several risk
factors to improve the identification of patients at high risk
[55].
There are several existing models for risk assessment
in Europe; however, the most widely used is FRAX
[56]. FRAX, released in 2008, is a computer-based al-
gorithm that calculates the probability of fracture in in-
dividuals using age, body mass index, BMD (optionally)
and risk factors such as whether the patient had a prior
fragility fracture, their parental history of hip fracture,
whether they smoke, drink, have rheumatoid arthritis
and other factors that increase the risk for osteoporosis
[57]. FRAX models are currently available for 68 coun-
tries and are publicly available on the official FRAX
website [58]. There are also several other fracture risk
assessment models available.
Table 8 provides a summary of the access to FRAX and
other risk assessment models in the EU6. Country-specific
FRAX models exist in all 6 countries. Alternative assessment
models are also recommended for use in Germany, Italy and
the UK. The German DVO model, developed in 2006, is a
Germany-specific risk assessment model which requires the
use of BMDmeasurements [59, 60]. DeFra is an Italy-specific
extension of the FRAX model, which allows for comparison
of the BMD in different fracture sites and the inclusion of
more variables [61]. QFracture® in the UK was developed
in 2009, and uses variables that are available through
healthcare records in the UK; it does not include BMD [62].
For more details, see the Appendix (18: Fracture risk
assessment).
Specific guidelines for the use of FRAX and other risk
models are noted on official national health service websites
for all countries except for Italy. The Italian Ministry of health
does not recommend specific risk models but suggests that
risk models may be useful in assessing the probability of fra-
gility fracture. Other organizations like the Italian Society for
Orthopaedics and Traumatology recommended FRAX or
DeFra.
The uptake of FRAX in 2010 and 2017 is shown in Fig. 28
as the number of calculations/million persons in the general
population. The UK and Sweden had the highest usage of
FRAX, whereas the lowest uptakes were seen in Germany
and Italy. Considering all countries in the EU6, the usage
use of FRAX increased by almost 74% in 2017 compared to
2010. The highest increase was seen in the UK, France and
Sweden (~ 100%), whereas in both Germany and Italy, the
usage of FRAX decreased was reduced in 2017 compared to
2010. In both Germany and Italy, the usage of FRAX de-
creased in 2017 compared to 2011. The decrease in the use
of FRAX in both Italy and Germany may relate to the avail-
ability of other risk models such as the German specific DVO
model and DeFra in Italy. For more details, see the Appendix
(18: Use of FRAX).
Fracture liaison services
A fracture liaison service (FLS) is a multi-disciplinary health
care delivery model for secondary fracture prevention. FLS
aims to systemically identify, treat and refer all eligible pa-
tients within a local population who have suffered a fragility
fracture with the aim of reducing their risk of subsequent
fractures. The FLS concept was first introduced in teaching
hospitals in Scotland and has grown in popularity around the
world due to its effectiveness in preventing secondary frac-
tures [70]. A growing body of published evidence suggests
Table 9 Meta-analysis results for outcomes of FLS [78]
Outcome measure Effect of FLS (absolute change) 95% CI Duration of follow-up (months) Number of studies
BMD testing + 24% (0.18 to 0.29) 3–26 37
Treatment initiation + 20% (0.16 to 0.25) 3–72 46
Adherence + 22% (0.13 to 0.31) 3–48 9
Refracture − 5% (− 0.08 to − 0.03) 6–72 11
Table 10 Country-specific
studies on the economic impact of
FLS
Country Type Estimate Source
Sweden ICER (cost-eff) € 14,029 (per QALY gained) [79]
UK (hip patients) ICER (cost-eff) €22,700-€26,600 (per QALY gained) [80]
UK Cost savings €23,800/lifetime/1000 patients [74]
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that FLSs are a cost-effective care delivery model that has the
potential to reduce the risk of refracture, increase the number
of high-risk patients being treated and improve adherence to
treatment. [71–77].
A recently published systematic literature review and meta-
analysis based on 159 scientific publications studied several
important outcomes of fracture liaison services [78]. Albeit,
with a variety of study designs used, all the studies attempted
to estimate the impact of a FLS compared to the absence of
such a program. The meta-analysis indicated that FLS im-
proved the rate of fractured patients getting BMD tests,
starting treatment and adhering to treatment by about 20%
(Table 9). The results also showed a significant reduction in
the refracture rates.
Even though the meta-analysis showed an overall positive
impact of FLSs, it did not consider that there are different
types of FLS models which is likely to be associated with
different outcomes. For example, some FLS only identify pa-
tients and inform them without taking any further actions
whereas other more complete FLS identify, investigate, treat
and monitor the patient. In another recent study, the evidence
of different FLS model types (A to D) on fracture risk, DXA
referrals, and other patient outcomes were reviewed [77]. The
most complete FLS model (type A) was associated with re-
duction in refracture risk (hazard ratio [HR] 0.18–0.67 over 2–
4 years), increased assessment of BMD (relative risk [RR] 2–
3), increased treatment initiation (RR 1.5–4.25) and adherence
to treatment (65–88% at 1 year).
Along with the literature focusing on the impact of FLSs,
several studies have analysed the cost-effectiveness and cost
savings of providing FLSs. Estimates in Sweden and the UK
for the economic impact of FLSs are shown in Table 10. For
more details, see the Appendix (19: Fracture liaison service
impact).
The large variation between different types of FLS and
their evaluation complicates the assessment of the overall ben-
efits of FLS andmerits of a specific FLSmodel. Initiatives that
promote standardised outcome frameworks for assessing FLS
and increased collaboration between providers include the
Capture the Fracture® and the UK FLS-Database Audit [81,
82].
Capture the Fracture®
One effort to encourage cooperation between FLS providers is
Capture the Fracture® (CtF), a global initiative of IOF to
‘facilitate the implementation of coordinated, multi-
disciplinary models of care for secondary fracture prevention’
[73]. CtF has created a set of internationally endorsed stan-
dards and guides for best practice and has assembled the larg-
est network of individual FLS providers in the world. CtF
provides resources, tools and educational programmes to
bridge the gap between FLS providers and helps in the crea-
tion of new FLS.
This growing network of FLS providers is mapped on their
website (https://www.capturethefracture.org/map-of-best-
practice-page)spain and provides a rating of the existing
service providers in a given area. To be included in the CtF
network, the provider must undergo a standardised external
audit to determine the quality of their services. Table 11 shows
the star ratings for registered FLS providers in the countries of
interest. A value of 4, 3 and 2 was applied to gold, silver and
bronze, respectively and a 1 to providers currently under
review. Spain and the UK lead in terms of the number of
registered FLS, whereas Spain, the UK and Sweden score
highly in the average score/FLS.
Table 12 Potential reduced burden by closing the FLS gap
Country Fractures avoided
(per year)
Fractures avoided
per 1000 FLS patients
Reduction in annual fracture-
related cost (million €)
Net impact on annual
burden (million €)
Net impact
per patient (€)
Reduction in annual
burden (QALYs)
France 2665 10.0 −38.0 20.0 75.0 1036
Germany 5423 13.9 −75.4 8.2 21.0 2335
Italy 2868 7.2 −55.7 −4.8 −12.0 1602
Spain 1249 5.4 −18.4 20.0 86.0 584
Sweden 1371 22.7 −22.4 −2.3 −38.0 596
UK 5686 16.2 −75.5 −1.4 −4.0 2705
EU6 19,262 11.3 −285.4 39.7 16.2 8858
Table 11 Number of Capture the Fracture FLS ratings by country and
scores [73]
Country Total Gold Silver Bronze Other Score Score/
FLS
France 20 0 3 9 8 35 1.75
Germany 2 0 1 0 1 4 2.0
Italy 13 1 3 2 7 24 1.8
Spain 65 13 13 22 17 152 2.3
Sweden 5 0 4 1 0 14 2.8
UK 25 6 11 1 7 66 2.6
EU6 130 20 35 35 40 285 2.2
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There is currently no publicly available information on
how many fragility fractures are referred to an FLS within
the EU6 countries. A survey sent to a selected number of
FLSs in the EU6, enrolled in IOF’s Capture the Fracture
network, asked for the percentage of hospitals and general
practitioners (GPs), on a national level, that have a system to
refer fractured patients. The responses varied between an av-
erage of 2.8% in Italy, to 37.5% in Sweden for hospital refer-
rals and 1–10% for GP referrals. In the UK, the National
Osteoporosis Society has estimated that 55% of the UK pop-
ulation has access to a FLS. For more details, see the
Appendix (20: Capture the fracture).
Closing the FLS gap
Given the available evidence showing the potential benefits of
FLSs and the sub optimal coverage of such models in the
EU6, it is as relevant to highlight the FLS treatment gap.
When applying the information on fracture epidemiology,
costs, current FLS coverage previously described in this report
and evidence of FLS outcomes based on Wu et al. [78], it is
possible to assess the potential impact a complete coverage of
FLS could have on the burden of fragility fractures.
It is estimated that, 19,262 number of subsequent fragility
fractures could be avoided every year by extending the access
to FLS for all citizens above 50 years of age in EU6. The
reduction in the annual fracture-related cost associated with
these fractures is €285.4 million. Adding the additional cost
related to increased FLS resources and drug administration the
net impact is an increased cost of €39.7 million but at a gain of
8858 quality-adjusted life years (Table 12). The cost per
QALY gained of an FLS extension would be €3108, an esti-
mate that can be considered cost-effective in all countries and
probably underestimated because of conservative assumptions
on the costs related to other osteoporotic fractures. The varia-
tion between countries is mainly driven by differences in frac-
ture risk and cost of osteoporosis drugs.
Executive summary
Osteoporosis is a disease that weakens the bones and increases
the risk of fragility fractures, where bones can break from a
fall from a standing height or less. In Western Europe, about 1
in 3 women and 1 in 5 men at or above the age of 50 years will
fracture during their lifetime. The number of fragility fractures
and cases of osteoporosis is increasing worldwide, creating an
increasing burden to society.
This report provides an overview and a comparison of the
burden and management of fragility fractures in six European
countries (France, Germany, Italy, Spain, Sweden, UK), here-
after referred to as EU6.
Key findings
& The total number of fragility fractures in the EU6 is esti-
mated to increase from 2.7 million in 2017 to 3.3 million
in 2030; an increase of 23.3%.
& The annual fracture-related costs in the EU6 are projected
to increase from a total €37.5 billion 2017 to €47.4 billion
in 2030; an increase of 27%.
& The number of disability-adjusted life years (DALYs) per
1000 individuals’ age 50 years or more in EU6 due to
fragility fractures was estimated at 21 years. This is a
higher estimate compared to some other chronic diseases
such as stroke (13 DALYs per 1000) and chronic obstruc-
tive pulmonary disease (COPD) (15 DALYs per 1000).
& The risk of refracture is highest immediately after a frac-
ture. This has been referred to as the period of imminent
risk; this phenomenon suggests that there is an opportuni-
ty to optimize the benefits of fracture prevention by
treating patients as soon as possible after occurrence of a
fracture.
& The treatment gap (defined as the percent eligible individ-
uals not receiving treatment with osteoporosis drugs) in
EU6 in year 2017 is estimated to be 73% for women and
63% for men. Compared to analysis from the year 2010,
this is a marked increase from 56% in women and 47% in
men.
& The proportion of patients starting a pharmacological
treatment in the year after a fracture is low. In France,
Sweden and Spain, 85%, 84% and 72% of fracture pa-
tients remained untreated 1 year after fracture,
respectively.
& A fracture liaison service (FLS) is a multi-disciplinary
health care delivery model for secondary fracture preven-
tion. This health care delivery model has become more
common in recent years, but its coverage is still low.
& A growing body of evidence suggests that FLS are cost-
effective care delivery models that have the potential to
increase the number of high-risk patients being treated,
improve adherence to treatment and reduce the risk of
refracture.
& A FLS provides an opportunity to improve early post-
fracture patient identification and reduce the treatment
gap.
& If FLS could be further expanded to reach all fracture
patients in the EU6, 19,262 additional fractures every year
would be avoided, and fracture-related costs would be
reduced by €285.5 million.
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Key results by country
Key Results (mean values*) France Germany Italy Spain Sweden UK EU6
Lifeme risk of hip fracture in women 
from age 50 
11.0% 17.1% 16.7% 9.8% 22.8% 17.2% 15.1%
Percentage increase in fragility 
fractures by 2030
24.4% 18.5% 22.4% 28.8% 26.6% 26.2% 23.3%
Annual fracture related cost per 
capita (€)
83 137 159 91 199 79 114
Percentage increase in fracture 
related costs by 2030
26.4% 23.2% 26.2% 30.6% 29.4% 30.2% 27.7%
Percentage increase in Quality-
Adjusted Life-Years (QALYs) lost by 
2030
26.4% 22.4% 24.7% 29.8% 27.2% 28.2% 25.6%
Fracture related Disability-Adjusted 
Life-Years (DALYs) per 1,000 people
17 24 20 12 32 24 21
Fracture related sick days per 1,000 
people
16 32 24 15 36 21 24
Relave care hours related to 
fractures per 1,000 people
138 - 882 756 191 248 443
Overall treatment gap in women (%) 77% 78% 73% 68% 76% 64% 73%
Post fracture treatment gap in 
women (%) - osteoporoc fracture
85% - - 72% 84% - 72%-85%
Post fracture treatment gap in 
women (%) - hip fracture
- - - 68% 84% 49% 49%-84%
FRAX model with guideline available 
(yes/no)
YES NO⁺ YES YES YES YES NA
Change in the uptake of FRAX from 
2010 to 2017 (%)
+100% -6% -16% +17% +118% +99% +75%
Number of fracture liaison services 
(FLS) enrolled in the Capture the 
Fracture (CtF) network (total)
15 3 12 54 5 17 106
Potenal reducon in number of 
fragility fractures (per 1,000 
populaon) with improved coverage 
of FLS
10.0 13.9 7.2 5.4 22.7 16.2 11.3
Potenal reducon in fracture related 
costs (€) (per 1,000 of new FLS 
paents) with improved coverage of 
FLS 
-143 -193 -139 -79 -370 -216 -168
*Mean value if not otherwise stated
+FRAX is available in Germany, but no guideline currently endorses its use
Colours indicate ranking among countries (from green = best to red = worst)
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